title: Imaging mass spectrometry reveals elevated nigral levels of dynorphin neuropeptides in L-DOPA-induced dyskinesia in rat model of Parkinson's disease.
abstract: L-DOPA-induced dyskinesia is a troublesome complication of L-DOPA pharmacotherapy of Parkinson's disease and has been associated with disturbed brain opioid transmission. However, so far the results of clinical and preclinical studies on the effects of opioids agonists and antagonists have been contradictory at best. Prodynorphin mRNA levels correlate well with the severity of dyskinesia in animal models of Parkinson's disease; however the identities of the actual neuroactive opioid effectors in their target basal ganglia output structures have not yet been determined. For the first time MALDI-TOF imaging mass spectrometry (IMS) was used for unbiased assessment and topographical elucidation of prodynorphin-derived peptides in the substantia nigra of a unilateral rat model of Parkinson's disease and L-DOPA induced dyskinesia. Nigral levels of dynorphin B and alpha-neoendorphin strongly correlated with the severity of dyskinesia. Even if dynorphin peptide levels were elevated in both the medial and lateral part of the substantia nigra, MALDI IMS analysis revealed that the most prominent changes were localized to the lateral part of the substantia nigra. MALDI IMS is advantageous compared with traditional molecular methods, such as radioimmunoassay, in that neither the molecular identity analyzed, nor the specific localization needs to be predetermined. Indeed, MALDI IMS revealed that the bioconverted metabolite leu-enkephalin-arg also correlated positively with severity of dyskinesia. Multiplexing DynB and leu-enkephalin-arg ion images revealed small (0.25 by 0.5 mm) nigral subregions with complementing ion intensities, indicating localized peptide release followed by bioconversion. The nigral dynorphins associated with L-DOPA-induced dyskinesia were not those with high affinity to kappa opioid receptors, but consisted of shorter peptides, mainly dynorphin B and alpha-neoendorphin that are known to bind and activate mu and delta opioid receptors. This suggests that mu and/or delta subtype-selective opioid receptor antagonists may be clinically relevant for reducing L-DOPA-induced dyskinesia in Parkinson's disease.
authors: Department of Pharmaceutical Biosciences, Drug Safety and Toxicology, Uppsala University, Uppsala, Sweden.
authors: Anna
authors: A
authors: Ljungdahl
authors: Jörg
authors: J
authors: Hanrieder
authors: Maria
authors: M
authors: Fälth
authors: Jonas
authors: J
authors: Bergquist
authors: Malin
authors: M
authors: Andersson
mesh_terms: D000818:Animals; D004399:Dynorphins / Q000378:metabolism*; D020820:Dyskinesias / Q000209:etiology / Q000378:metabolism*; D004745:Enkephalins / Q000235:genetics / Q000378:metabolism; D005260:Female; D007150:Immunohistochemistry; D007980:Levodopa / Q000633:toxicity*; D008297:Male; D013058:Mass Spectrometry / Q000379:methods*; D051379:Mice; D018345:Mice, Knockout; D010300:Parkinson Disease / Q000378:metabolism*; D011498:Protein Precursors / Q000235:genetics / Q000378:metabolism; D051381:Rats; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
chemical_list: D004745:Enkephalins; D011498:Protein Precursors; D007980:Levodopa; D004399:Dynorphins; C033660:preproenkephalin